Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study
vivani | April 4, 2023
Read More
Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
vivani | March 31, 2023
Read More
Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division
vivani | March 21, 2023
Read More
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates
vivani | November 14, 2022
Read More
Vivani Medical to Present at the ThinkEquity Investor Conference
vivani | November 14, 2022
Read More
Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)
vivani | August 31, 2022
Read More
Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.
vivani | August 30, 2022
Read More
Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting
vivani | July 29, 2022
Read More
Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study
vivani | July 18, 2022
Read More
Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®
vivani | April 14, 2022
Read More
Blog Navigation
Contact Us
To learn more about Vivani or LIBERATE-1, the upcoming First-in-Human trial of our long-term GLP-1 implant, please fill out the form.